CXCL10 and hepatocellular carcinoma: Our study identified increased serum CXCL10 levels during Atez/Bev therapy as a predictor of therapeutic efficacy in patients with BCLC stage C HCC, but these findings were not replicated in patients with BCLC stage A or B HCC.